Advances in In-Vivo CAR-T Delivery

In‑vivo CAR‑T therapies represent one of the most exciting frontiers in cell and gene therapy, with the potential to transform how these powerful treatments are delivered and accessed. By reprogramming immune cells directly inside the body, this approach could eliminate complex manufacturing steps, reduce costs, and enable faster, more scalable “off‑the‑shelf” treatments for cancer, autoimmune disease, and beyond. 

In the past year alone, multibillion‑dollar deals and strategic collaborations have underscored growing confidence from large pharmaceutical companies, signaling that in‑vivo CAR‑T may play a central role in the next generation of immunotherapies. 

This panel will examine the technologies enabling in‑body cell engineering, review emerging clinical data, and provide insight into the investment and partnering trends shaping the field.